Uhmontpellier
Montpellier, 34295, France
NCT Number: NCT04643496
Aim: The aim of this study was to assess the accuracy of the C-reactive protein as an early predictor of intra-abdominal septic complicationss after ileocolic resection for Crohn disease.
Methods: Data collected between January 2010 and March 2020 will be analyzed. Informations about preoperative, peroperative and post operative will be collected. The outcome after surgery will be analysed according to the comprehensive complication index.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Observational
Montpellier, 34295, France
In colorectal surgery, inflammatory markers (CRP, PCT) are used systematically in the postoperative period as an early predictor of postoperative complications and in particular the prediction of anastomotic leaks and intra-abdominal septic complications.
Indeed, the occurrence of an anastomotic leak (5 to 15% of cases) involves the introduction of antibiotics, the carrying out of invasive procedures which can go as far as reoperation (and the establishment of ostomy) and always increases the length of stay and the cost of hospitalization. It is therefore essential to benefit from the most sensitive and specific tools to detect this serious and sometimes lethal complication at an early stage.
Numerous studies have evaluated and demonstrated the value of monitoring the CRP in the early postoperative period to detect the occurrence of an anastomotic leak. However, the majority of these studies presented heterogeneous populations for two reasons: all types of colorectal surgery interventions were included (right colectomy, transverse colectomy, left colectomy and anterior resection of the rectum) and multiple surgical indications were taken into account (colorectal cancer, inflammatory bowel disease, colonic diverticulosis).
In addition, a 2015 study comparing the postoperative monitoring of markers of inflammation after ileocolic resection of patients with, on the one hand, Crohn's disease and, on the other, colon cancer showed a greater inflammatory reaction in patients with Crohn's disease (in particular on POD1, 4, 5 and 6) without identifying a threshold value. This increased inflammatory response can be explained by a greater inflammatory state than in the general population: bacterial translocation due to an alteration of the mucosal barrier aggravated by immunodeficiency.
It thus appears that the cut-off values usually used (170-175 mg/l on POD3 and 125mg/l on POD4) are probably not suitable for the postoperative monitoring of these patients and for prediction of intra-abdominal septic complications.
No study to date has identified a threshold value of postoperative CRP that can predict the occurrence of postoperative anastomotic fistula and intra-abdominal septic complications after ileocecal resection for Crohn's disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Laparoscopic or open Ileocolic resection
Time frame: 90 days (after surgery)
Rate of intra-abdominal septic complications
Time frame: 90 days (after surgery)
Anastomotic leak rate
Time frame: 90 days (after surgery)
Morbidity according to the Clavien Dindo Classification
Time frame: 90 days (after surgery)
Mortality
Time frame: 90 days (after surgery)
Hemorragic complications
Time frame: 90 days (after surgery)
Reoperation rate
Time frame: 90 days (after surgery)
Post-operative rate of stomy
Time frame: 90 days (after surgery)
Readmission rate
University Hospital, Montpellier
Other
Post-operative CRP Monitoring After Ileo-colic Resection in Crohn's Disease Patients
Acronym: C-ICR-CD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03846778
Crohn Disease, Digestive System Diseases
Montpellier, France
View Trial DetailsNCT04673357
Crohn Disease, Digestive System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT05013905
Crohn Disease, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsNCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial Details